Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 306 recruiting now early-phase tilt #3 of 28,707 conditions

Obesity: early-phase trial registry

306 of 1,057 indexed Obesity trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3 of 28,707 conditions by registered trial count.

1,057 US clinical trials · 306 currently recruiting · #3 of 28,707 conditions by registered trial count

Obesity: 1,057 US clinical trials tracked, 306 recruiting.

Obesity is the subject of 1,057 registered US clinical trials on ClinicalTrials.gov, 306 of them currently open to new participants. 107 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 48 of these trials.

Enrollment posture brief

Registry condition obesity

OPEN 306 | RECR 29% | LATE 107 | EARLY 196 | RANK #3 | SPON 48

Nearest open-share peer: Metastatic Pancreatic Adenocarcinoma (29% recruiting · 38 trials)

Prostate Cancer36.7%Depression35.7%Breast Cancer33.8%Obesity (this)29%Healthy20.5%
Open-enrollment share among volume-matched conditions near Obesity

Obesity lists 306 open slots (29% of 1,057 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Obesity is recruiting below its size-band peers.

    306 of 1,057 indexed trials (28.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Obesity trials is spread across many organizations.

    Eli Lilly and Company accounts for 48 of 1,057 trials (4.5%). 314 distinct sponsors appear on at least one study for this condition label.

  3. Typical Obesity enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,054 trials that report a genuine target (sentinel values excluded). 555 of those (52.7%) plan for fewer than 100 participants.

  4. Obesity research is mostly interventional.

    894 interventional and 163 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 195Phase 2101Phase 369Phase 438

Phase Distribution

PhaseTrial count
Phase 1 95
Phase 2 101
Phase 3 69
Phase 4 38

Named interventions

Most-linked intervention names on Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
108 trials
Tirzepatide Drug
30 trials
Semaglutide Drug
20 trials
Placebo Other
18 trials
Liraglutide Drug
10 trials
Exercise Behavioral
10 trials
Placebo Dietary supplement
10 trials
Orforglipron Drug
9 trials

US sites by state

Facility locations filed on Obesity trials. A trial with sites in several states counts in each.

California 197 trials
Florida 132 trials
Texas 95 trials
North Carolina 93 trials
New York 91 trials
Pennsylvania 86 trials
Massachusetts 80 trials
Illinois 73 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Obesity page

1,057 registered trials, 306 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obesity condition card totals 1,057 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.